Literature DB >> 16511425

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.

Bénédicte Roquebert1, Isabelle Malet, Marc Wirden, Roland Tubiana, Marc-Antoine Valantin, Anne Simon, Christine Katlama, Gilles Peytavin, Vincent Calvez, Anne-Geneviève Marcelin.   

Abstract

We investigated, in the protease and GAG cleavage sites, the role of minority populations on the evolution of resistance to a subsequent boosted protease inhibitor (PI) regimen after a first failure to nelfinavir. Two pathways were observed: the addition of mutations to a currently dominant genotype when minority variants are not shown, or the emergence of a minority variant as a dominant strain. These minor species, not detected by standard genotype, may influence PI susceptibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511425     DOI: 10.1097/01.aids.0000202650.03279.69

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

2.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

3.  Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory.

Authors:  Boaz Avidor; Shirley Girshengorn; Natalia Matus; Hadass Talio; Svetlana Achsanov; Irene Zeldis; Ilana S Fratty; Eugene Katchman; Tal Brosh-Nissimov; David Hassin; Danny Alon; Zvi Bentwich; Israel Yust; Sharon Amit; Relly Forer; Ina Vulih Shultsman; Dan Turner
Journal:  J Clin Microbiol       Date:  2013-01-02       Impact factor: 5.948

4.  Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.

Authors:  Art F Y Poon; Sergei L Kosakovsky Pond; Douglas D Richman; Simon D W Frost
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

5.  Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.

Authors:  Saverio G Parisi; Caterina Boldrin; Mario Cruciani; Giangiacomo Nicolini; Isabella Cerbaro; Vinicio Manfrin; Federico Dal Bello; Elisa Franchin; Marzia Franzetti; Maria C Rossi; Anna M Cattelan; Laura Romano; Maurizio Zazzi; Massimo Andreoni; Giorgio Palù
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

6.  Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.

Authors:  Dawn Eggert; Prasanta K Dash; Nawal Serradji; Chang-Zhi Dong; Pascal Clayette; Francoise Heymans; Huanyu Dou; Santhi Gorantla; Harris A Gelbard; Larisa Poluektova; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2009-06-21       Impact factor: 3.478

7.  Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.

Authors:  Andrea Hauser; Julius Sewangi; Paulina Mbezi; Festo Dugange; Inga Lau; Judith Ziske; Stefanie Theuring; Claudia Kuecherer; Gundel Harms; Andrea Kunz
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

8.  RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.

Authors:  Wei Shao; Mary Kearney; Frank Maldarelli; John W Mellors; Robert M Stephens; Jeffrey D Lifson; Vineet N KewalRamani; Zandrea Ambrose; John M Coffin; Sarah E Palmer
Journal:  Retrovirology       Date:  2009-11-04       Impact factor: 4.602

Review 9.  Human Immunodeficiency Virus Gag and protease: partners in resistance.

Authors:  Axel Fun; Annemarie M J Wensing; Jens Verheyen; Monique Nijhuis
Journal:  Retrovirology       Date:  2012-08-06       Impact factor: 4.602

10.  Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing.

Authors:  Vijay Bansode; Grace P McCormack; Amelia C Crampin; Bagrey Ngwira; Ram K Shrestha; Neil French; Judith R Glynn; Simon A Travers
Journal:  BMC Infect Dis       Date:  2013-01-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.